# Adma Biologics Inc. (ADMA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $2.08B  
**Price:** $8.48 (+4.43%)

> ADMA Biologics Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases in the United States and internationally. Its primary products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies indicated for primary humoral immunodeficiency (PI), and Nabi-HB, a human polyclonal antibody product for acute exposure to Hepatitis B. The company operates through segments including ADMA BioManufacturing for immune globulin production and development, Plasma Collection Centers for source plasma, and corporate overhead. ADMA Biologics Inc. maintains a fully U.S.-based, vertically integrated supply chain, encompassing plasma collection, manufacturing, and commercialization. It also sells plasma-derived intermediate fractions and provides laboratory contracting services. Founded in 2004 and headquartered in Ramsey, New Jersey, with additional facilities in Boca Raton, Florida, ADMA Biologics Inc. focuses on serving immunodeficient patients and those at risk for specific infections through its end-to-end commercial operations.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $510M | $293M | $191M | $147M | — |
| 2024 | $426M | $220M | $139M | $198M | — |
| 2023 | $258M | $89M | $22M | -$28M | — |
| 2022 | $154M | $35M | -$39M | -$66M | — |
| 2021 | $81M | $1M | -$58M | -$72M | — |
| 2020 | $42M | -$19M | -$65M | -$76M | — |
| 2019 | $29M | -$10M | -$41M | -$48M | — |
| 2018 | $17M | -$25M | -$60M | -$66M | — |
| 2017 | $23M | -$6M | -$39M | -$44M | — |
| 2016 | $11M | $4M | -$17M | -$20M | — |
| 2015 | $7M | $3M | -$16M | -$18M | — |
| 2014 | $6M | $2M | -$16M | -$17M | — |
| 2013 | $3M | $1M | -$15M | -$16M | — |
| 2012 | $1M | $449,062 | -$8M | -$7M | — |
| 2011 | $761,042 | $553,472 | -$5M | -$6M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $624M | $147M | $477M | $88M | $72M |
| 2024 | $489M | $140M | $349M | $103M | $72M |
| 2023 | $329M | $194M | $135M | $51M | — |
| 2022 | $348M | $196M | $152M | $87M | — |
| 2021 | $276M | $135M | $141M | $51M | — |
| 2020 | $208M | $119M | $88M | $56M | — |
| 2019 | $127M | $101M | $26M | $27M | — |
| 2018 | $89M | $69M | $20M | $27M | $3M |
| 2017 | $108M | $68M | $40M | $43M | $3M |
| 2016 | $24M | $28M | -$4M | $10M | $2M |
| 2015 | $24M | $23M | $820,974 | $10M | — |
| 2014 | $27M | $21M | $6M | $17M | — |
| 2013 | $32M | $10M | $22M | $26M | — |
| 2012 | $16M | $6M | $9M | $13M | — |
| 2011 | $3M | $3M | $385,816 | $87,771 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $50M | $23M | $28M |
| 2024 | $119M | $8M | $110M |
| 2023 | $9M | $5M | $4M |
| 2022 | -$60M | $14M | -$73M |
| 2021 | -$112M | $14M | -$126M |
| 2020 | -$102M | $13M | -$115M |
| 2019 | -$76M | $4M | -$80M |
| 2018 | -$63M | $2M | -$65M |
| 2017 | -$37M | $3M | -$40M |
| 2016 | -$18M | $73,410 | -$18M |
| 2015 | -$15M | $26,073 | -$15M |
| 2014 | -$15M | $2M | -$17M |
| 2013 | -$11M | $196,635 | -$11M |
| 2012 | -$7M | $118,853 | -$7M |
| 2011 | -$1M | $270 | -$1M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ADMA)